SGHT · Sight Sciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $77.36M | $79.87M | $81.06M | $71.33M | $27.64M |
| Cost of Revenue | $10.70M | $11.58M | $11.88M | $12.36M | $9.21M |
| Gross Profit | $66.67M | $68.28M | $69.17M | $58.97M | $18.43M |
| R&D | $14.61M | $17.99M | $17.56M | $22.86M | $8.87M |
| SG&A | $89.16M | $100.83M | $108.89M | $120.06M | $41.74M |
| Total Operating Expenses | $103.77M | $118.82M | $126.45M | $142.92M | $50.62M |
| D&A | $487.0K | $712.0K | $614.0K | $710.0K | $554.0K |
| Operating Income | ($37.10M) | ($50.53M) | ($57.27M) | ($83.95M) | ($32.19M) |
| Interest Expense | $5.14M | $4.66M | $5.41M | $4.47M | $2.40M |
| Income Tax | $10.0K | $236.0K | $110.0K | $47.0K | $61.0K |
| Net Income | ($38.43M) | ($51.51M) | ($55.55M) | ($86.24M) | ($34.69M) |
| EPS - Basic | ($0.74) | ($1.03) | ($1.14) | ($1.80) | - |
| EPS - Diluted | ($0.74) | ($1.03) | ($1.14) | ($2.36) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $91.97M | $120.36M | $138.13M | $185.00M | $260.69M |
| Accounts Receivable | $9.74M | $10.79M | $14.29M | $15.15M | $8.71M |
| Inventory | $7.77M | $6.33M | $7.85M | $6.11M | $3.48M |
| Accounts Payable | $1.34M | $1.69M | $1.73M | $2.69M | $3.35M |
| Current Assets | $112.73M | $139.77M | $162.87M | $209.68M | $277.04M |
| Total Assets | $115.30M | $142.84M | $166.65M | $213.07M | $280.19M |
| Current Liabilities | $11.03M | $15.47M | $12.25M | $17.82M | $13.50M |
| Long-term Debt | $40.30M | $39.36M | $31.71M | $33.31M | $32.66M |
| Total Liabilities | $51.36M | $55.32M | $46.44M | $53.00M | $48.08M |
| Stockholders' Equity | $63.94M | $87.52M | $120.22M | $160.08M | $232.11M |
| Retained Earnings | ($384.72M) | ($346.30M) | ($294.79M) | ($239.24M) | ($153.00M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($29.69M) | ($22.35M) | ($47.18M) | ($75.97M) | ($32.17M) |
| Investing Cash Flow | ($224.0K) | ($385.0K) | ($791.0K) | ($970.0K) | ($953.0K) |
| Financing Cash Flow | $1.79M | $4.96M | $1.10M | $1.25M | $73.40M |
| CapEx | $224.0K | $385.0K | $791.0K | $970.0K | $953.0K |
| Free Cash Flow | ($29.92M) | ($22.74M) | ($47.98M) | ($76.94M) | ($33.13M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 86.2% | 85.5% | 85.3% | 82.7% | 66.7% |
| Operating margin | -48.0% | -63.3% | -70.7% | -117.7% | -116.5% |
| EBITDA margin | -47.3% | -62.4% | -69.9% | -116.7% | -114.5% |
| Net margin | -49.7% | -64.5% | -68.5% | -120.9% | -125.5% |
| Free cash flow margin | -38.7% | -28.5% | -59.2% | -107.9% | -119.9% |
| FCF / Net income | 0.78 | 0.44 | 0.86 | 0.89 | 0.95 |
| R&D / Revenue | 18.9% | 22.5% | 21.7% | 32.0% | 32.1% |
| SG&A / Revenue | 115.2% | 126.2% | 134.3% | 168.3% | 151.0% |
| Effective tax rate | - | - | - | - | - |
| Return on assets | -33.3% | -36.1% | -33.3% | -40.5% | -12.4% |
| Return on equity | -60.1% | -58.8% | -46.2% | -53.9% | -14.9% |
| Return on invested capital | -28.1% | -31.5% | -29.8% | -34.3% | -9.6% |
| Liquidity | |||||
| Current ratio | 10.22 | 9.04 | 13.29 | 11.77 | 20.52 |
| Quick ratio | 9.52 | 8.63 | 12.65 | 11.43 | 20.26 |
| Cash ratio | 8.34 | 7.78 | 11.27 | 10.38 | 19.30 |
| Leverage | |||||
| Debt / Equity | 0.63 | 0.45 | 0.26 | 0.21 | 0.14 |
| Debt / Assets | 0.35 | 0.28 | 0.19 | 0.16 | 0.12 |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | -7.2x | -10.8x | -10.6x | -18.8x | -13.4x |
| Equity multiplier | 1.80 | 1.63 | 1.39 | 1.33 | 1.21 |
| Liabilities / Assets | 0.45 | 0.39 | 0.28 | 0.25 | 0.17 |
| Efficiency | |||||
| Asset turnover | 0.67 | 0.56 | 0.49 | 0.33 | 0.10 |
| Inventory turnover | 1.38 | 1.83 | 1.51 | 2.02 | 2.65 |
| Days sales outstanding | 46d | 49d | 64d | 78d | 115d |
| Days inventory outstanding | 265d | 199d | 241d | 181d | 138d |
| Days payable outstanding | 46d | 53d | 53d | 79d | 133d |
| Cash conversion cycle | 265d | 195d | 252d | 179d | 120d |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | 6.5x | 2.1x | 2.1x | 2.0x | - |
| P / S | 5.3x | 2.3x | 3.1x | 4.6x | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | -3.1% | -1.5% | 13.6% | 158.1% | - |
| Revenue CAGR (3y) | 2.7% | 42.4% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | -2.4% | -1.3% | 17.3% | 220.0% | - |
| Operating income growth (YoY) | 26.6% | 11.8% | 31.8% | -160.8% | - |
| Net income growth (YoY) | 25.4% | 7.3% | 35.6% | -148.6% | - |
| EPS growth (YoY) | 28.2% | 9.6% | 51.7% | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | -31.6% | 52.6% | 37.6% | -132.2% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | -26.9% | -27.2% | -24.9% | -31.0% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$77.36M totalSurgical Glaucoma$75.72M · 97.9%
Dry Eye$1.64M · 2.1%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-2.00
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Sight Sciences against the 5 most active filers in the same SIC group.